Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk (NYSE:NVO) regarding their new ...